Company intelligence / Profile preview

Zhejiang Yangshengtang Biotechnology

Hangzhou, Zhejiang Sheng, Chinadnb.com ↗

Ownership: Private
Employees: ~5770
Development stage: Other

Overview

Zhejiang Yangshengtang Biotechnology is developing innovative biologics, including a recombinant human PD‑1 antibody herpes simplex virus therapy in Phase 1 for CNS and metastatic brain tumors. The company or its affiliates have also participated in the development and commercialization of prophylactic vaccines, such as COVID‑19 and HPV vaccines, with several products approved in China[3][5].

Therapeutic areas: Infectious DiseasesOncology
Modalities: Monoclonal antibodyOncolytic virus therapyRecombinant protein
Industry: Biotech

Partnerships

Xiamen UniversityXiamen Innovax Biotech Co., Ltd.Beijing Wantai Biological

Beyond the preview

Go deeper on Zhejiang Yangshengtang Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Yangshengtang Biotechnology.

Explore the full profile